Startups
Business development / Federal government / Health

Personal Genome Diagnostics’ new kind of cancer test is going to be used by the VA

The company's liquid biopsy analyzes cancer genes from a blood test, no human tissue required.

Personal Genome Diagnostics (PGDx) received a new contract from the U.S. Department of Veterans Affairs to provide a test for cancer that does not require tissue samples.
The Canton-based company makes a liquid biopsy, which tests for cancer by evaluating 64 genes that are associated with cancer.
The test can be conducted through a blood test, rather than obtaining tissue samples through a traditional biopsy or conducting an ultrasound. The test can also be conducted multiple times during treatment, providing a “real-time livestream of what’s happening at the genetic level in the patient’s tumor or tumors,” PGDx Manager for Translational Science and Diagnostics John Simmons told Technical.ly last year.
The test will be offered to advanced cancer patients who are receiving treatment in the VA, according to the company.
The company’s work on liquid biopsy got attention from the White House last year, when Vice President Joe Biden included PGDx among the group of experts working on the Cancer Moonshot.
The new contract is an expansion of work with the VA for PGDx, which was founded by Johns Hopkins researchers. PGDx also has a contract to provide its product which analyzes tumors on the genetic level.
The company raised a $21.4 million Series A in 2015.

Engagement

Join the conversation!

Find news, events, jobs and people who share your interests on Technical.ly's open community Slack

Trending

What does SXSW mean for cities now?

Total solar eclipse 2024 is a big deal. Here’s what to expect

In Baltimore, building digital literacy took — and takes — a village

A 22-year-old Towson biology major's journey brought her to a deeper purpose

Technically Media